Media ReleasesChimeric Therapeutics

View All Chimeric Therapeutics News


Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report


Chimeric Therapeutics Limited (“the Company”) (ASX: CHM), a clinical stage cell therapy company, is pleased to provide a summary of its activities for the quarter ended 30 June 2021.

Key highlights this quarter include:

• Successful completion of the 1st patient cohort in the CLTX CAR T phase 1 clinical trial
• Initiation of dosing in 2nd patient cohort in the CLTX CAR T phase 1 clinical trial
• Acceptance of the 1st CLTX CAR T abstract by ASCO (American Society of Clinical Oncology)
• Appointment of Dr Li Ren as VP, Technical Operations
• Healthy financial position, with $22.4 million in cash and equivalents as of 30 June 2021

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.